Ofatumumab is an antibody treatment commonly used to treat chronic leukemia. In low doses, ofatumumab is suitable for multiple sclerosis. Research on this treatment has shown that B-cell depletion and humoral immunity occurs faster than in the case of other intravenously administered B-cell-targeted therapies.
Ofatumumab (Kesimpta) was approved by the U.S. Food and Drug Administration (FDA) in August 2020 to treat adults with relapsing MS, including:
- Clinically isolated syndrome (CIS)
- Relapsing-remitting MS (RRMS)
- Active secondary progressive MS (SPMS)
In clinical trials, Kesimpta reduces relapse rates, though MS Studies aren't clear on how Kesimpta alters disease activity in MS or affects disabilities. However, researchers know that the antibody targets B-cells and binds to the CD20 protein under the surface.
Kesimpta treatment involves self-administered injections. The first three doses are self-injected weekly. Then, on week four, you'll start injecting the antibody once monthly.
You may experience some reactions at the injection site. Talk to your doctor about any such reactions immediately.
Side effects that occurred in more than one person in 100 include:
- Injection-site reactions, including redness, pain, itching, and swelling
- Injection-related reactions, including fever, headache, muscle pain, chills, and tiredness
- Head colds
- Chest infections
- Urinary tract infections
- Cold sores (oral herpes)
- Decreased levels of immunoglobulins that help protect against infection
During the two trials for MS, ofatumumab seemingly reduced relapses by 51% to 59%. When compared to results associated with the other drug studied, teriflunomide (Aubagio), these findings make ofatumumab a more desirable treatment for relapsing MS. You can talk to your doctor about trying this treatment. They'll help you determine if it's right for you.
If you're in the process of injecting Kesimpta and are having strong reactions, stop immediately. It would be best if you discussed all symptoms with your doctor before proceeding with injections.
